EDNRA

(redirected from Endothelin A receptor)

EDNRA

A gene on chromosome 4q31.22 that encodes endothelin-A receptor, a member of the endothelin receptor group of G-protein-coupled receptors, located primarily in the vascular endothelial cells where they play a role in vasoconstriction, vasodilation, bronchoconstriction and cell proliferation.

Molecular pathology
EDNRA polymorphisms have been linked to migraine headache resistance.
Mentioned in ?
References in periodicals archive ?
22, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease).
ABBOTT PARK, Illinois, November 22, 2010 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease).
Bakris noted that Gilead Sciences made a splash earlier this year when it released interim results showing dramatic additional blood pressure reductions with its selective endothelin A receptor antagonist darusentan in patients who had resistant hypertension despite maximal doses of a three-drug regimen that included a diuretic.
The NDA for our lead drug candidate Thelin(TM) (sitaxsentan sodium), an endothelin A receptor antagonist for the treatment of PAH, is now under active review by the Cardio- Renal Division of the FDA.
Derek's extensive background in launching new drugs, including pre-launch work on Zetia(R) and Clarinex(R), will be invaluable as we drive towards commercialization of sitaxsentan, our once daily, selective endothelin A receptor antagonist for the treatment of pulmonary arterial hypertension.
TBC3711 is greater than 100,000-fold selective in the targeting of the endothelin A receptor versus the endothelin B receptor.
We are determined to bring patients with PAH, many of whom are children or young adults, an important alternative to current therapies, one which combines endothelin A receptor selectivity with the convenience of once daily dosing.
SPP301 is a once daily oral endothelin A receptor antagonist that Speedel licensed from Roche in October 2000.
a partnership formed by ICOS Corporation (Nasdaq:ICOS) and Texas Biotechnology Corporation (AMEX:TXB), announced that patients are being recruited for the STRIDE (Sitaxsentan To Relieve ImpaireD Exercise in pulmonary hypertension) Trial, a pivotal Phase 2/3 study with sitaxsentan, an oral endothelin A receptor antagonist.
a partnership formed by ICOS Corporation (Nasdaq:ICOS) and Texas Biotechnology Corporation (AMEX:TXB), announced today the initiation of Phase I testing of TBC3711, its second oral endothelin A receptor antagonist to enter clinical development.
For these reasons, we expect that, unlike other heart failure therapies, the endothelin A receptor antagonists may have beneficial effects on systemic or pulmonary vascular remodeling," stated Wilson S.

Full browser ?